Search results for "Liver Neoplasms."

showing 10 items of 733 documents

Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.

2019

Abstract Introduction and objectives Non-alcoholic steatohepatitis (NASH) indication of liver transplant (LT) has increased recently, whereas alcoholic cirrhosis remains a major indication for LT. To characterize NASH-related cases and to compare the post-transplant outcome of these two conditions represents our major objective. Material and methods Patients undergoing LT for NASH between 1997 and 2016 were retrieved. Those transplanted between 1997 and 2006 were compared to an “age and LT date” matched group of patients transplanted for alcoholic cirrhosis (ratio 1:2). Baseline features and medium-term outcome measures were compared. Results Of 1986 LT performed between 1997 and 2016, 40 (…

Liver CirrhosisMaleAlcoholic liver diseaseCirrhosisHepatocellular carcinomamedicine.medical_treatmentSpecialties of internal medicineLiver transplantationGastroenterologyCohort Studies0302 clinical medicinePostoperative ComplicationsLiver Cirrhosis AlcoholicNon-alcoholic Fatty Liver DiseaseCause of DeathHyperuricemiaRenal InsufficiencyCardiovascular risk factorsIncidence (epidemiology)Liver NeoplasmsGeneral MedicineMiddle AgedSurvival RateTreatment OutcomeRC581-951Cardiovascular Diseases030220 oncology & carcinogenesisHepatocellular carcinomaHypertension030211 gastroenterology & hepatologyFemaleAlcoholAdultmedicine.medical_specialtyCarcinoma HepatocellularHyperuricemia03 medical and health sciencesYoung AdultInternal medicinemedicineDiabetes MellitusHumansObesityAgedDyslipidemiasRetrospective StudiesHepatologybusiness.industrynutritional and metabolic diseasesOverweightmedicine.diseasedigestive system diseasesLiver TransplantationSpainSteatohepatitisNeoplasm Recurrence LocalbusinessDyslipidemiaAnnals of hepatology
researchProduct

Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma

2003

With the widespread use of ultrasonography (US) and computerized tomography (CT), the usefulness of α-fetoprotein assay in the diagnosis of hepatocellular carcinoma (HCC) has decreased. The aim of our study was to evaluate the best cut-off value for serum α-fetoprotein to discriminate between liver cirrhosis (LC) and HCC and the factors influencing levels in a Sicilian population. Three hundred and seventy-two patients with LC and 197 with HCC-associated LC were studied. The etiology was: HCV in 288 cases (77.4%) of LC and 147 cases (75%) of HCC; HBV in 31 cases (8.3%) of LC and 15 cases (7.6%) of HCC; HCV/HBV in 21 cases (5.6%) of LC and 6 cases (3.0%) of HCC; non-viral in 32 cases (8.6%) …

Liver CirrhosisMaleCancer ResearchCarcinoma HepatocellularHepatocellular carcinomaMedicine (all)Liver NeoplasmsMiddle AgedLiver cirrhosiDiagnosis DifferentialOncologyROC CurveArea Under CurveUltrasoundHumansRegression AnalysisFemalealpha-Fetoproteinsα-FetoproteinDiagnosiAgedNeoplasm StagingRetrospective Studies
researchProduct

Radio-frequency thermal ablation (RFTA) of small hepatocellular carcinoma in patients with cirrhosis. Experience at a single tertiary referral center

2005

AIM: Radio-frequency thermal ablation (RFTA) may prolong the survival of patients with small hepatocellular carcinoma (HCC) associated with cirrhosis. The aim of this study was to evaluate efficacy and safety of RFTA. METHODS: We performed the Kaplan-Meier analysis to estimate the survival rate in 69 consecutive patients with HCC (mean age 66+/-6.5 years; 44/25 male/female; 56 Child-Pugh class A and 13 Child-Pugh class B) treated by RFTA. A single lesion was observed in 60/69 (87%), two lesions in 8/69 (11.6 %), and 3 lesions in 1/69 (1.4 %) of patients. The tumor size was = or <3 cm in 60/69 (87%). RESULTS: Twenty-two patients died during follow-up. Overall survival rates were 81%, 66%, an…

Liver CirrhosisMaleCarcinoma Hepatocellularhepatocellular carcinoma thermal ablationLiver NeoplasmsHyperthermia InducedCancer Care FacilitiesMiddle AgedSurvival AnalysisDisease-Free SurvivalTreatment OutcomeItalyCatheter AblationHumansFemaleProspective StudiesAged
researchProduct

IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma.

2011

Recently, a link between high levels of circulating IL-6 and hepatocellular carcinoma (HCC) has been proposed. In addition, single nucleotide polymorphisms (SNPs) in the promoter region of the IL-6 gene have been reported to be related to several inflammatory-related conditions, including cancer. The purpose of this article is: (1) to evaluate the frequencies of SNPs in the IL-6 promoter region at position -174 and IL-6 serum levels in a group of patients with HCC and underlying liver cirrhosis (LC), and compare them with a group of LC patients without HCC; (2) to determine whether a possible correlation exists between the allelic variations, IL-6 serum levels, and the risk of developing HC…

Liver CirrhosisMaleCirrhosisCarcinoma HepatocellularGenotypeSNPSingle-nucleotide polymorphismEnzyme-Linked Immunosorbent AssayBioinformaticsBiochemistryPolymerase Chain ReactionPolymorphism Single NucleotideGene FrequencyGeneticsmedicineHumansAlleleHCCInterleukin 6Molecular BiologyGeneIL-6biologyInterleukin-6Liver NeoplasmsPromotermedicine.diseaseHepatocellular carcinomabiology.proteinCancer researchIL-6 -174G/C polymorphism liver cirrhosis hepatocellular carcinomaMolecular MedicineFemaleRestriction fragment length polymorphismPolymorphism Restriction Fragment LengthBiotechnology
researchProduct

Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules

2018

Background & Aims The use of contrast enhanced ultrasound (CEUS) for the diagnosis of hepatocellular carcinoma (HCC) in cirrhosis was questioned because of the risk of a false positive diagnosis in cases of cholangiocarcinoma. The American College of Radiology has recently released a scheme (CEUS Liver Imaging Reporting and Data System [LI-RADS®]) to classify lesions at risk of HCC investigated by CEUS. The aim of the present study was to validate this LI-RADS scheme for the diagnosis of HCC. Methods A total of 1,006 nodules from 848 patients with chronic liver disease at risk of HCC were collected in five Italian centers and retrospectively analyzed. Nodules were classified as LR-5, (HCC) …

Liver CirrhosisMaleCirrhosisContrast enhanced ultrasoundContrast MediaChronic liver diseaseGastroenterology030218 nuclear medicine & medical imagingCholangiocarcinoma0302 clinical medicineDiagnosisMedicineTomographyWashoutUltrasonographyUltrasoundLiver NeoplasmsMiddle AgedMagnetic Resonance ImagingX-Ray ComputedLiverHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleRadiologymedicine.symptomAlgorithmsContrast-enhanced ultrasoundAdultmedicine.medical_specialtyCarcinoma HepatocellularDiagnosis Differential03 medical and health sciencesInternal medicineHumansDiagnostic ErrorsneoplasmsAgedLiver Imaging Reporting And Data System (LI-RADS)Hepatologybusiness.industryCarcinomaSettore MED/09 - MEDICINA INTERNAReproducibility of ResultsHepatocellularRetrospective cohort studyHistologyNodule (medicine)medicine.diseaseImage Enhancementdigestive system diseasesArterial hyperenhancementDifferentialbusinessTomography X-Ray Computed
researchProduct

Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interfer…

2016

none 48 no Background: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens. Methods: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infec…

Liver CirrhosisMaleCirrhosisDatabases FactualGastroenterologyHCV-infected cirrhotic patients; hepatocellular carcinoma; HCC; sustained viral eradication; SVR; interferon0302 clinical medicineRetrospective StudiePharmacology (medical)Prospective StudiesHCV-infected cirrhotic patientsHCCProspective cohort studyAged 80 and overLiver NeoplasmsGastroenterologyvirus diseasesHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaCatheter AblationInterferon030211 gastroenterology & hepatologyFemaleLiver cancerHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularSVRLiver CirrhosiAntiviral AgentsFollow-Up Studie03 medical and health sciencesInternal medicinemedicineCarcinomaEarly Hepatocellular CarcinomaHumansAgedRetrospective StudiesAntiviral AgentHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNARetrospective cohort studymedicine.diseasedigestive system diseasesSurgeryProspective Studiesustained viral eradicationInterferonsNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients

2014

Summary Background Morphological, haemodynamic and clinical stages of cirrhosis have been proposed, although no definite staging system is yet accepted for clinical practice. Aim To investigate whether clinical complications of cirrhosis may define different prognostic disease stages. Methods Analysis of the database from a prospective inception cohort of 494 patients. Decompensation was defined by ascites, bleeding, jaundice or encephalopathy. Explored potential prognostic stages: 1, compensated cirrhosis without oesophago-gastric varices; 2, compensated cirrhosis with varices; 3, bleeding without other complications; 4, first nonbleeding decompensation; 5, any second decompensating event.…

Liver CirrhosisMaleCirrhosisSettore MED/09 - Medicina InternaDatabases Factualmedicine.medical_treatmentLiver transplantationGastroenterologyCohort StudiesModel for End-Stage Liver DiseaseAscitesEsophageal and Gastric VariceMedicinePharmacology (medical)Prospective StudiesProspective cohort studyLiver NeoplasmsGastroenterologyAscitesJaundiceMiddle AgedPrognosisLiver NeoplasmAsciteDisease ProgressionFemalemedicine.symptomHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularPrognosiLiver CirrhosiJaundiceEsophageal and Gastric VaricesRisk AssessmentFollow-Up StudieInternal medicineHumansDecompensationAgedHepatologybusiness.industrymedicine.diseaseLiver TransplantationProspective StudieCohort StudiebusinessVaricesFollow-Up Studies
researchProduct

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.

2018

Background &amp; Aims: Studies have produced conflicting results of the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus–associated cirrhosis treated with direct-acting antivirals (DAAs). Data from clinics are needed to accurately assess the occurrence rate of HCC in patients with cirrhosis in the real world. Methods: We collected data from a large prospective study of 2,249 consecutive patients (mean age = 65.4 years, 56.9% male) with hepatitis C virus–associated cirrhosis (90.5% with Child-Pugh class A and 9.5% with Child-Pugh class B) treated with DAAs from March 2015 through July 2016 at 22 academic and community liver centers in Sicily, Italy. HCC occurren…

Liver CirrhosisMaleCirrhosisSettore MED/09 - Medicina InternaSustained Virologic ResponseHepacivirusGastroenterology0302 clinical medicineRESIST-HCVRisk FactorsHepatocellular Carcinoma (HCC)MedicineLiver Cancer RiskProspective StudiesProspective cohort studySettore MED/12 - GastroenterologiaIncidence (epidemiology)IncidenceLiver NeoplasmsGastroenterologyHepatitis CMiddle AgedCirrhosis; Direct Antiviral Agents (DAAs); Hepatocellular Carcinoma (HCC); RESIST-HCV; Sustained Virological Response (SVR); hepatitis C Virus (HCV); liver cancer risk; reduction; sofosbuvirCirrhosisItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomahepatitis C Virus (HCV)030211 gastroenterology & hepatologyFemaleHumanmedicine.medical_specialtyCarcinoma HepatocellularDirect Antiviral Agents (DAAs)Liver CirrhosiRESIST-HCV Liver Cancer Risk Reduction SofosbuvirAntiviral AgentsFollow-Up Studie03 medical and health sciencesInternal medicineHumansIn patientSustained Virological Response (SVR)AgedReductionAntiviral AgentHepaciviruHepatologybusiness.industryProportional hazards modelRisk FactorHepatitis C Chronicmedicine.diseasedigestive system diseasesProspective StudieChild-Pugh Class BSofosbuvirbusinessFollow-Up Studies
researchProduct

Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals

2018

Background: Despite the dramatic improvement in viral eradication rates that has been reached with direct antiviral agents (DAAs),the real benefit of viral eradication after DAAs on hepatocellular carcinoma (HCC) development is still controversial. Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAAtreated HCV-cirrhotic patients and to identify potential predictors of HCC development. Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhotic patients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy and followed-up for one year after therapy. 161 patients had a previous …

Liver CirrhosisMaleCirrhosisSustained Virologic ResponseHepatocellular carcinomaDirect antiviral agentsDIRECT ACTING ANTIVIRALSGastroenterologyCohort Studies0302 clinical medicineRisk FactorsChronicIncidence (epidemiology)Liver NeoplasmsGastroenterologyMiddle AgedHepatitis CTumor recurrenceCirrhosis; Direct antiviral agents; HCV; Hepatocellular carcinoma; Aged; Antiviral Agents; Carcinoma Hepatocellular; Cohort Studies; Disease Progression; Female; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Risk Factors; alpha-Fetoproteins; Sustained Virologic ResponseItalyLocalCirrhosis030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease ProgressionPortal hypertension030211 gastroenterology & hepatologyFemalealpha-FetoproteinsCohort studymedicine.medical_specialtyCarcinoma HepatocellularEarly RecurrenceAntiviral Agents03 medical and health sciencesInternal medicinemedicineHumansneoplasmsAgedCirrhosiHepatologybusiness.industryCarcinomaHepatocellularHepatitis C Chronicmedicine.diseasedigestive system diseasesNeoplasm RecurrenceDirect antiviral agentNeoplasm Recurrence LocalCirrhosis; Direct antiviral agents; HCV; Hepatocellular carcinomabusiness
researchProduct

Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study.

2005

Background & Aims: Transcatheter arterial chemoembolization (TACE) currently is used as a palliative treatment for patients with unresectable hepatocellular carcinoma (HCC), but its efficacy still is debated. Our aim was to assess the impact of TACE on patient survival and to identify prognostic factors for survival. Methods: Fifty-six cirrhotic patients with unresectable HCC undergoing at least :1 course of TACE were matched 1:1. for sex, age (in 5-year periods), parameters of Child-Pugh score, Okuda stage, and tumor type with a control group who had received only supportive care. Results: The 2 groups were comparable for cause of cirrhosis, alpha-fetoprotein serum levels, and Cancer of th…

Liver CirrhosisMaleCirrhosisTime FactorsPrognostic systemGastroenterologyOily chemoembolizationHepatic ArteryCause of DeathAscitesValidationMedicineStage (cooking)CIRRHOSISUnivariate analysisAntibiotics AntineoplasticLiver NeoplasmsGastroenterologyLiver-TransplantationMiddle AgedHEPATOCELLULAR CARCINOMA; CIRRHOSIS; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; SURVIVAL; SIDE EFFECTSPrognosisTreatment OutcomeItalyRandomized controlled trialHepatocellular carcinomaSURVIVALFemalemedicine.symptommedicine.medical_specialtyCarcinoma HepatocellularMultivariate-analysiTransarterial chemoembolizationInternal medicineSIDE EFFECTSCarcinomaHumansHEPATOCELLULAR CARCINOMAChemoembolization TherapeuticTranscatheter arterial chemoembolizationSurvival analysisAgedEpirubicinNeoplasm StagingCirrhosiHepatologybusiness.industrymedicine.diseaseSurvival AnalysisSurgeryLipiodol chemoembolizationTRANSCATHETER ARTERIAL CHEMOEMBOLIZATIONCase-Control StudiesMultivariate AnalysisbusinessFollow-Up StudiesClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct